2024 - 2032 年前列腺癌诊断市场机会、成长动力、产业趋势分析与预测

Prostate Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年10月01日 | 出版商:

Global Market Insights Inc. | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球前列腺癌诊断市场估值为45亿美元，预计2024年至2032年复合年增长率为10.5%。推动的，以及对创新诊断方法的重大投资。这些综合因素正在推动市场向前发展。随着前列腺癌变得越来越普遍，特别是在老龄化人群中，对及时、准确的诊断工具的需求日益增长。公共卫生运动和宣传工作鼓励男性定期接受检查，进一步推动市场需求。

此外，对早期检测和个人化治疗方案的关注正在促进先进诊断技术的采用。市场按测试类型分为诊断测试和影像测试，其中诊断测试处于领先地位。 2023 年，诊断测试产生了 29 亿美元的收入，这主要归功于其在早期检测中的关键作用。 PSA（前列腺特异性抗原）测试尤其重要，因为它可以测量血液中这种与癌症相关的蛋白质的水平。

PSA 检测通常用于常规健康检查，特别是对于 50 岁以上的男性，随着检测灵敏度的提高，这些诊断方法将继续在癌症检测中发挥至关重要的作用。就癌症类型而言，前列腺癌占前列腺癌病例的 95% 以上，2023 年产生的收入最高，为 41 亿美元。这种影响前列腺细胞的癌症是最常见的，推动了对专业诊断工具的需求。北美市场 2023 年营收为 18 亿美元，预计到 2032 年将以 9.9% 的复合年增长率大幅增长。此外，FDA 等监管机构支持快速采用创新诊断解决方案，包括液体活检和基因检测，进一步增强市场的成长潜力。

市场范围
开始年份	2023年
预测年份	2024-2032
起始值	45 亿美元
预测值	111 亿美元
复合年增长率	10.5%

产业生态系统分析
产业影响力
- 成长动力
  - 摄护腺癌盛行率增加
  - 技术进步
  - 提高意识和筛检倡议
  - 摄护腺癌诊断测试日益普及
- 产业陷阱与挑战
  - 缺乏熟练的专业人员
  - 严格规定
成长潜力分析
技术景观
监管环境
报销场景
主要市场趋势
波特的分析
PESTEL分析
差距分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按测试类型，2021 - 2032 年

主要趋势
诊断测试
- PSA
- 摄护腺切片
- 分子/基因组测试
- 其他诊断测试
影像学检查
- 经直肠超音波 (TRUS)
- 核磁共振成像
- CT扫描
- 其他影像学检查

第 6 章：市场估计与预测：按癌症类型，2021 - 2032 年

主要趋势
摄护腺腺癌
小细胞癌
其他前列腺癌类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
医院
诊断实验室
癌症研究机构
其他最终用途

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 波兰
- 瑞典
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 印尼
- 菲律宾
- 越南
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 哥伦比亚
- 智利
- 秘鲁
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 土耳其
- 伊朗
- 以色列
- 中东和非洲其他地区

第 9 章：公司简介

Abbott Laboratories
AdvaCare Pharma
Beckman Coulter, Inc. (Danaher Corporation)
Becton, Dickinson and Company
BIOMERIEUX
F. Hoffmann-La Roche Ltd.
FUJIFILM Holdings Corporation
GE Healthcare Technologies Inc.
Glycanostcs Ltd.
Healgen
KOELIS
Koninklijke Philips NV
Metamark Genetics, Inc.
miR Scientific
Myriad Genetics, Inc.
Proteomedix
Siemens Healthineers AG
Veracyte

简介目录

Product Code: 6107

The Global Prostate Cancer Diagnostics Market was valued at USD 4.5 billion in 2023 and is projected to grow at a CAGR of 10.5% from 2024 to 2032. This expansion is driven by the rising incidence of prostate cancer, increasing awareness about risk factors, technological advancements, and significant investments in innovative diagnostic methods. These combined factors are pushing the market forward. As prostate cancer becomes more prevalent, especially among aging populations, there is a growing need for timely and accurate diagnostic tools. Public health campaigns and awareness efforts encourage men to undergo regular screenings, further propelling market demand.

Additionally, the focus on early detection and personalized treatment options is boosting the adoption of advanced diagnostic technologies. The market is segmented by test type into diagnostic tests and imaging tests, with diagnostic tests leading the way. In 2023, diagnostic tests generated USD 2.9 billion in revenue, largely due to their critical role in early detection. The PSA (prostate-specific antigen) test is particularly crucial, as it measures the level of this cancer-related protein in the blood.

PSA testing is commonly used in routine health checks, particularly for men over 50, and with advancements in testing sensitivity, these diagnostics continue to play a vital role in cancer detection. In terms of cancer types, the prostatic adenocarcinoma, which accounts for over 95% of prostate cancer cases, generated the highest revenue at USD 4.1 billion in 2023. This type of cancer, affecting the gland cells of the prostate, is the most prevalent, driving the need for specialized diagnostic tools. The North America market, which accounted for USD 1.8 billion in revenue in 2023, is anticipated to grow significantly at a CAGR of 9.9% through 2032. This growth is fueled by a combination of high awareness levels, advanced healthcare infrastructure, and regular screening programs. Additionally, regulatory bodies such as the FDA support the rapid adoption of innovative diagnostic solutions, including liquid biopsy and genetic testing, further enhancing the market's growth potential.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$4.5 Billion
Forecast Value	$11.1 Billion
CAGR	10.5%

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of prostate cancer
  - 3.2.1.2 Technological advancement
  - 3.2.1.3 Surging awareness and screening initiatives
  - 3.2.1.4 Increasing popularity of prostate cancer diagnostic tests
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of skilled professionals
  - 3.2.2.2 Stringent regulations
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Reimbursement scenario
3.7 Key market trends
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Diagnostics tests
- 5.2.1 PSA
- 5.2.2 Prostate biopsy
- 5.2.3 Molecular/ genomic test
- 5.2.4 Other diagnostics tests
5.3 Imaging tests
- 5.3.1 Transrectal ultrasound (TRUS)
- 5.3.2 MRI
- 5.3.3 CT Scan
- 5.3.4 Other imaging tests

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Prostatic adenocarcinoma
6.3 Small cell carcinoma
6.4 Other prostate cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Cancer research institutes
7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Poland
- 8.3.7 Sweden
- 8.3.8 Netherlands
- 8.3.9 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Philippines
- 8.4.8 Vietnam
- 8.4.9 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Colombia
- 8.5.5 Chile
- 8.5.6 Peru
- 8.5.7 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Turkey
- 8.6.5 Iran
- 8.6.6 Israel
- 8.6.7 Rest of Middle East and Africa